Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
Peter Emtage has been promoted to VP, Immune Mediated Therapies, at MedImmune, the global biologics R&D subsidiary of AstraZeneca.
The role will focus on immune mediated therapies for cancer (IMT-C) and, said MedImmune, “the rapidly growing trend of [the company’s] IMT-C portfolio assets to be developed in combinations, across project team lines.”
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
And microbiology awards to research scientists and Médecins Sans Frontières.